"The New Molecular Entity Evolocumab, One Kind of PCSK9 Inhibitor, Reduce Plasma Small Size LDL-Cholesterol Levels by Using a New Standardized Method of Measuring LDL Size"
written by Ikuo Inoue, Ryo Kubota, Shohan Yanagi, Masumi Akita, Takanari Nakano, Shigehiro Katayama, Akira Shimada, Mistuhiko Noda,
published by Open Journal of Molecular and Integrative Physiology, Vol.7 No.1, 2017
has been cited by the following article(s):
  • Google Scholar
  • CrossRef